☆ 4.6 Article

The Impact on Cost-Effectiveness of Accounting for Generic Drug Pricing: Four Case Studies

VALUE IN HEALTH (2023)

Related references

Note: Only part of the references are listed.

Review Economics

Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications

Peter J. Neumann et al.

Summary: This study investigated how health technology assessment (HTA) organizations worldwide have addressed drug genericization in cost-effectiveness analyses (CEAs). It analyzed a large sample of published CEAs and found that the majority of these studies did not consider assumptions about future generic prices for drugs, potentially leading to misrepresentation of long-term opportunity costs. The study highlights the need for clearer guidance on when CEAs should account for genericization and include other price dynamics.

VALUE IN HEALTH (2022)

Add to Collection

Article Health Care Sciences & Services

Patients' Access to 2018 FDA-Approved Drugs 1 Year Post

Ari D. Panzer et al.

Summary: This study examined the adoption of 2018 FDA-approved drugs by US commercial health plans. The results showed that health plans imposed fewer coverage restrictions on cancer treatments, orphan drugs, and biosimilars than on drugs not in those categories. This has implications for patients' access to innovative therapies.

AMERICAN JOURNAL OF MANAGED CARE (2022)

Add to Collection

Article Medicine, General & Internal

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Kausik K. Ray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Pharmacology & Pharmacy

Patent term restoration for top-selling drugs in the United States

Reed F. Beall et al.

DRUG DISCOVERY TODAY (2019)

Add to Collection

Letter Medicine, General & Internal

Prices of Generic Drugs Associated with Numbers of Manufacturers

Chintan V. Dave et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Editorial Material Medicine, General & Internal

Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs

Anastasia Khvorova

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Economics

Innovation in the pharmaceutical industry: New estimates of R&D costs

Joseph A. DiMasi et al.

JOURNAL OF HEALTH ECONOMICS (2016)

Add to Collection

Article Health Care Sciences & Services

Decline In Economic Returns From New Drugs Raises Questions About Sustaining Innovations

Ernst R. Berndt et al.

HEALTH AFFAIRS (2015)

Add to Collection

Article Public, Environmental & Occupational Health

Utilization, price, and spending trends for antidepressants in the US Medicaid program

Yan Chen et al.

RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY (2008)

Add to Collection

Article Economics

Generic Competition and Market Exclusivity Periods in Pharmaceuticals

Henry G. Grabowski et al.

MANAGERIAL AND DECISION ECONOMICS (2007)

Add to Collection

Article Medicine, General & Internal

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics

LA Prosser et al.

ANNALS OF INTERNAL MEDICINE (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.